Key result
Pretreatment with verapamil prevented the isoproterenol-induced reduction of high energy phosphate compounds and increases of inorganic phosphate and lactate in the rat myocardium.
Why the study?
Does verapamil prevent isoproterenol-induced transmural metabolic lesions in the rat heart?
Does verapamil prevent isoproterenol-induced transmural metabolic lesions in the rat heart?
Absolute Event Rate: 1.01% vs 0.79%
In a rat model, verapamil pretreatment prevented isoproterenol-induced myocardial metabolic impairment, preserving high-energy phosphates and reducing lactate accumulation.
Suggests metabolic protection by verapamil in catecholamine injury; hypothesis-generating and leaves open human translation.
The effect of verapamil on the isoproterenol (ISO)-induced transmural metabolic lesion in the left ventricular wall was investigated in the rat heart. The treatment with ISO 2.5 mg/Kg s.c. on 2 consecutive days resulted in significant decreases of creatine phosphate in the subendocardium (ENDO) and of adenosine triphosphate in the ENDO and the subepicardium. On the other hand, inorganic phosphate (Pi) and lactate (LA) were increased in both layers. These changes were more prominent in the ENDO. Pretreatment with verapamil 25 mg/Kg s.c. prevented the reduction of high energy phosphate compounds and the increases of Pi and LA in both layers by ISO.
No takes yet. Share an insight, caveat, or question.
Higuchi et al. (1978) studied Isoproterenol-induced myocardial lesion (n=15). Verapamil vs. Isoproterenol alone was evaluated on Ratio of subendocardium to subepicardium for ATP content. Pretreatment with verapamil prevented the isoproterenol-induced reduction of high energy phosphate compounds and increases of inorganic phosphate and lactate in the rat myocardium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: